

Fluorotechnics \$12m IPO to expand global operations

Rapid sales growth – 98% of sales overseas

4 September 2008 – Sydney, Australia: Fluorotechnics Ltd, which produces and sells high value consumables in the \$18bn life science tools market lodged a prospectus for an initial public offering to raise up to \$12 million.

The Sydney-based company has developed valuable IP based on proprietary research conducted over the past decade. Fluorotechnics today has specialised manufacturing facilities at North Ryde in Sydney and near Stuttgart in Germany.

The company was established in 2002 with management and directors owning almost half of the issued shares. The company was spun-out of Macquarie University and the university remains a shareholder.

Fluorotechnics' offer of \$1.00 per share is due to open on 10 September and close on 10 October. When listed on the ASX Fluorotechnics will have 26-28 million shares on issue with a market capitalisation of \$26-28 million. BBY Limited is the lead manager of the float.

CEO Duncan Veal said the IPO fund raising, "would allow Fluorotechnics to ramp-up its production capability to meet the significant unmet demand for its proteomics products."

"The company's unique product suite has attracted a top-level sales and marketing team who have joined us from the current market leader, GE Healthcare."

Fluorotechnics has assembled an experienced board including John Fletcher, the former CEO of Coles Group and David Weber, the former president for the Biosciences Division of GE-Healthcare Americas region.

The other directors are the two founders of the Fluorotechnics business, Deloitte M&A partner Rick Taylor, chairman and Dr Duncan Veal, CEO as well as Günter Theßeling and Professor Peter Bergquist.

Last year Fluorotechnics acquired ETC Elektrophorese-Technik. ETC develops and manufactures high-end electrophoresis consumables including specialised high value gels and instrumentation for DNA and protein electrophoresis. ETC is located in Kirchentellinsfurt near Stuttgart Germany.

Sales of tools for proteomics experiments are on the rise as more and more researchers look to understand how the expression of proteins is linked with disease onset and progression. The merger brings together the skills needed to separate and detect proteins with high resolution and sensitivity.

In addition Fluorotechnics has entered into an agreement to acquire The Gel Company in the US. The Gel Company product suite enables Fluorotechnics & ETC's market leading fluorescent stains and non-fluorescent backed gels to operate on the installed base of equipment used in the typical proteomics workflow.

Fluorotechnics owns the intellectual property to a new family of fluorescent molecules – the *epicocconone* family of fluorophores that are used for detection and measurement in research diagnostics and quality control.

The company plans to bring 20 new products to the market in the next three years. Unlike many other biotechnology companies Fluorotechnics does not require FDA approvals to sell its consumables and is already generating revenues. 98 per cent of revenues are from overseas sales.

The minimum subscription is 6 million ordinary shares at \$1.00 per share. The prospectus was lodged with ASIC on 29 August 2008.

Important Information

The Prospectus contains important information about the offer. An electronic copy of the Prospectus can be viewed on Fluorotechnics website www.fluorotechnics.com. A person should consider the prospectus in deciding whether to acquire the shares on offer in Fluorotechnics. Anyone who wants to acquire shares in Fluorotechnics will need to complete the application form that accompanies the Prospectus.

Enquiries

Duncan Veal – CEO

Fluorotechnics

+61 2 9850 8185

dveal@fluorotechnics.com

Rudi Michelson

(Monsoon Communications)

+61 3 9620 3333

<http://www.fluorotechnics.com>